Grace Therapeutics, Inc. (GRCE) Net income 2019–2026
Grace Therapeutics, Inc. (GRCE) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$7.8MFY2026 · since FY2019: -$39.4M → -$7.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$7.8M | +18.6% |
| FY2025 | -$9.6M | +25.6% |
| FY2024 | -$12.9M | +69.7% |
| FY2023 | -$42.4M | -332.1% |
| FY2022 | -$9.8M | +50.1% |
| FY2021 | -$19.7M | +22.9% |
| FY2020 | -$25.5M | +35.2% |
| FY2019 | -$39.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GRCE financial trends
GRCE RevenueGRCE Net marginGRCE Gross profitGRCE Gross marginGRCE Operating incomeGRCE Operating marginGRCE Operating cash flowGRCE Free cash flowGRCE Capital expendituresGRCE Return on equityGRCE Stock buybacksGRCE Dividends paidGRCE Total assetsGRCE Total liabilitiesGRCE Shareholders’ equityGRCE overview →